PL2303264T3 - Sposoby leczenia stanów pośredniczonych alfa-adrenergicznie z użyciem pochodnych imidazoliny - Google Patents

Sposoby leczenia stanów pośredniczonych alfa-adrenergicznie z użyciem pochodnych imidazoliny

Info

Publication number
PL2303264T3
PL2303264T3 PL09763343T PL09763343T PL2303264T3 PL 2303264 T3 PL2303264 T3 PL 2303264T3 PL 09763343 T PL09763343 T PL 09763343T PL 09763343 T PL09763343 T PL 09763343T PL 2303264 T3 PL2303264 T3 PL 2303264T3
Authority
PL
Poland
Prior art keywords
methods
mediated conditions
alpha adrenergic
imidazoline derivatives
treating alpha
Prior art date
Application number
PL09763343T
Other languages
English (en)
Polish (pl)
Inventor
Wenkui K. Fang
Phong X. Nguyen
Ken Chow
Todd M. Heidelbaugh
Dario G. Gomez
Michael E. Garst
Santosh C. Sinha
W. Gil Daniel
E. Donello John
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of PL2303264T3 publication Critical patent/PL2303264T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
PL09763343T 2008-06-09 2009-06-05 Sposoby leczenia stanów pośredniczonych alfa-adrenergicznie z użyciem pochodnych imidazoliny PL2303264T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5983708P 2008-06-09 2008-06-09
PCT/US2009/046432 WO2009152052A1 (en) 2008-06-09 2009-06-05 Methods of treating alpha adrenergic mediated conditions
EP09763343.2A EP2303264B1 (en) 2008-06-09 2009-06-05 Methods of treating alpha adrenergic mediated conditions using imidazoline derivatives

Publications (1)

Publication Number Publication Date
PL2303264T3 true PL2303264T3 (pl) 2018-08-31

Family

ID=40823137

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09763343T PL2303264T3 (pl) 2008-06-09 2009-06-05 Sposoby leczenia stanów pośredniczonych alfa-adrenergicznie z użyciem pochodnych imidazoliny
PL15165926T PL2932968T3 (pl) 2008-06-09 2009-06-05 Związek do leczenia stanów pośredniczonych alfa-adrenergicznie

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL15165926T PL2932968T3 (pl) 2008-06-09 2009-06-05 Związek do leczenia stanów pośredniczonych alfa-adrenergicznie

Country Status (14)

Country Link
US (2) US8071636B2 (https=)
EP (3) EP2303264B1 (https=)
JP (1) JP5571072B2 (https=)
CN (1) CN102099032B (https=)
AU (1) AU2009257692A1 (https=)
CA (3) CA2959793A1 (https=)
DK (2) DK2932968T3 (https=)
ES (2) ES2672777T3 (https=)
HU (1) HUE039357T2 (https=)
PL (2) PL2303264T3 (https=)
PT (2) PT2303264T (https=)
SI (1) SI2303264T1 (https=)
TR (1) TR201802766T4 (https=)
WO (1) WO2009152052A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120083508A1 (en) * 2006-12-22 2012-04-05 Allergan, Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US7902247B2 (en) * 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
PL2605771T3 (pl) * 2010-08-16 2018-10-31 Allergan, Inc. Sposób aktywacji limfocytów t regulacyjnych za pomocą agonistów receptorów alfa-2b-adrenergicznych
JP6756435B2 (ja) * 2014-03-31 2020-09-16 ザ スクリプス リサーチ インスティテュート Ｔｒａｉｌ誘導のためのファーマコフォア
EP3700536A4 (en) 2017-10-27 2021-11-17 Shanghai Yao Yuan Biotechnology Co., Ltd. COMPOSITIONS AND PROCEDURES FOR MODULATING IMMUNE REACTION BY ACTIVATING ALPHA-PROTEIN KINASE 1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6708160A (https=) * 1966-06-30 1968-01-02
DE2259160A1 (de) * 1972-12-02 1974-06-06 Boehringer Sohn Ingelheim Neue substituierte 2-phenylaminoimidazoline, deren saeureadditionssalze und verfahren zur herstellung derselben sowie ihre verwendung als arzneimittel
US4256755A (en) 1980-04-28 1981-03-17 E. I. Du Pont De Nemours & Company Method of using N-substituted dihydro-2-oxazolamines as analgesics
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2002089794A1 (en) * 2001-05-07 2002-11-14 Universite Catholique De Louvain Method for treating neuropathic pain and pharmaceutical preparation therefor
EP1333028A1 (en) * 2002-01-31 2003-08-06 Boehringer Ingelheim Pharma GmbH & Co.KG 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
CN101287366A (zh) 2005-05-19 2008-10-15 拜尔农作物科学股份公司 杀虫的取代的苄基氨基杂环及杂芳基衍生物
WO2008123821A1 (en) * 2007-03-01 2008-10-16 Albireo Ab 4, 5-dihydro-lh-imidazol-2-amine derivatives for use in the treatment of respiratory, cardiovascular, neurological or gastrointestinal disorders
CN101687812A (zh) * 2007-07-02 2010-03-31 弗·哈夫曼-拉罗切有限公司 对痕量胺相关受体(taar)具有良好亲和性的2-咪唑啉化合物
WO2009052075A2 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Method of treating motor disorders with alpha-2b adrenergic receptor agonists

Also Published As

Publication number Publication date
PT2932968T (pt) 2018-03-13
EP2932968B1 (en) 2018-01-17
AU2009257692A1 (en) 2009-12-17
DK2303264T3 (en) 2018-05-22
EP2303264A1 (en) 2011-04-06
US8071636B2 (en) 2011-12-06
JP5571072B2 (ja) 2014-08-13
WO2009152052A8 (en) 2010-11-11
WO2009152052A1 (en) 2009-12-17
CA2744929C (en) 2017-07-25
JP2011522893A (ja) 2011-08-04
TR201802766T4 (tr) 2018-03-21
ES2665293T3 (es) 2018-04-25
EP2932968A1 (en) 2015-10-21
ES2672777T3 (es) 2018-06-18
HK1214132A1 (en) 2016-07-22
PL2932968T3 (pl) 2018-06-29
US20090306161A1 (en) 2009-12-10
CA2959793A1 (en) 2009-12-17
CA3133261A1 (en) 2009-12-17
CN102099032B (zh) 2014-07-09
EP2303264B1 (en) 2018-04-04
CN102099032A (zh) 2011-06-15
EP2377534A1 (en) 2011-10-19
SI2303264T1 (en) 2018-08-31
DK2932968T3 (en) 2018-03-12
PT2303264T (pt) 2018-05-14
HUE039357T2 (hu) 2018-12-28
CA2744929A1 (en) 2009-12-17
US20120035235A1 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
IL206544A0 (en) Methods of preparing quinazolinone derivatives
ZA201006648B (en) Methods of treatment
EP2258513A4 (en) WORKPIECE MOUNTING SYSTEM AND METHOD FOR MOUNTING A WORKPIECE
IL207100A0 (en) 2-amino-quinoline derivatives useful as inhibitors of b-secretase (bace)
IL211701A0 (en) Process for the preparation of bendamustine
EP2445885A4 (en) SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CHINESE INHIBITORS AND METHOD FOR THEIR USE
IL208232A0 (en) Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase
EP2313103A4 (en) PROCESS FOR TREATING A BLÉPHARITE
IL208136A0 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
IL207578A0 (en) Heterocyclic inhibitors of stearoyl-coa desaturase
EP2242854A4 (en) COMPOUNDS AND USES THEREOF
IL209447A0 (en) Method and apparatus for passive determination of tarbet parameters
PT2297115E (pt) Derivados de quinazolina
ZA201003301B (en) Mining machine and method of mining
PT2303264T (pt) Métodos de tratamento de condições mediadas adrenérgicas alfa utilizando derivados de imidazolina
VN25747A1 (en) Method of water treatment
EP2144886A4 (en) METHOD OF TREATING MELANOMA
EP2348858A4 (en) PROCESS FOR THE TREATMENT OF THROMBOCYTOPENIA
EP2362910A4 (en) METHOD FOR DNA CLONING
SI2347017T1 (sl) Postopki za konzerviranje ĺ˝ivalskih koĺ˝
EP2303284A4 (en) METHOD FOR TREATING BIPOLAR DISORDER
PL2391366T3 (pl) Podstawione benzimidazole do leczenia gwiaździaków
ZA201007680B (en) Method of treating metalliferrous materials
IL216456A0 (en) Method of treating frailty
EP2203432A4 (en) PROCESSING METHOD